Luis Antonio Corchete Sánchez

Has grant

Associate member

Broad Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Role of sex chromosomes in multiple myeloma

Open Date: 2024-01-01

Close Date:

Grant: Close

Investigación del splicing del RNA y de su regulación en el mieloma múltiple

Open Date: 2016-01-01

Close Date: 2018-01-01

Articles (17)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

In the last few years, nivolumab has become the standard of care for advanced-stage lung cancer patients. Unfortunately, up to 60% of patients do not respond to this treatment. In our study, we identified variations in gene expression related to primary resistance to immunotherapy. Bronchoscopy biopsies were obtained from advanced non-small cell lung cancer (NSCLC) patients previously characterized as responders or non-responders after nivolumab treatment. Ten tumor biopsies (from three responders and seven non-responders) were analyzed by the differential expression of 760 genes using the NanoString nCounter platform. These genes are known to be involved in the response to anti-PD1/PD-L1 therapy. All the patients were treated with nivolumab. Examining the dysregulated expression of 24 genes made it possible to predict the response to nivolumab treatment. Supervised analysis of the gene expression profile (GEP) revealed that responder patients had significantly higher levels of expression of CXCL11, NT5E, KLRK1, CD3G, GZMA, IDO1, LCK, CXCL9, GNLY, ITGAL, HLA-DRB1, CXCR6, IFNG, CD8A, ITK, B2M, HLA-B, and HLA-A than did non-responder patients. In contrast, PNOC, CD19, TP73, ARG1, FCRL2, and PTGER1 genes had significantly lower expression levels than non-responder patients. These findings were validated as predictive biomarkers in an independent series of 201 patients treated with nivolumab (22 hepatocellular carcinomas, 14 non-squamous cell lung carcinomas, 5 head and neck squamous cell carcinomas, 1 ureter/renal pelvis carcinoma, 120 melanomas, 4 bladder carcinomas, 31 renal cell carcinomas, and 4 squamous cell lung carcinomas). ROC curve analysis showed that the expression levels of ITK, NT5E, ITGAL, and CD8A were the best predictors of response to nivolumab. Further, 13/24 genes showed an adverse impact on overall survival (OS) in an independent, large series of patients with NSCLC (2166 cases). In summary, we found a strong association between the global GEP of advanced NSCLC and the response to nivolumab. The classification of NSCLC patients based on GEP enabled us to identify those patients who genuinely benefited from treatment with immune checkpoint inhibitors (ICIs). We also demonstrated that abnormal expression of most of the markers comprising the genomic signature has an adverse influence on OS, making them significant markers for therapeutic decision-making. Additional prospective studies in larger series of patients are required to confirm the clinical utility of these biomarkers.

Year:

2024

Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients’ samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (24)

María Dolores Ludeña

Catedrático de Universidad

University Hospital of Salamanca

SPAIN
View details

Claire Palles

Associate Professor

University of Birmingham

UNITED KINGDOM
View details

Elena Bueno Martínez

Profesora Ayudante Doctora

Universidad de Valladolid

SPAIN
View details

Cristina Carbonell

Profesora asociada en Ciencias de la Salud

Universidad de Salamanca

SPAIN
View details

Silvio Ragozzino

University Hospital Basel

SWITZERLAND
View details

José Perea

-

SPAIN
View details

Gema Santamaría

Professor

Universidad de Valladolid

SPAIN
View details

Jesús Seco-Calvo

Catedrático e investigador principal

Universidad de León

SPAIN
View details

Teresa Paíno

Universidad de Salamanca

SPAIN
View details

Alexandra Bacquelaine Veloso

Team Leader

University of Liege

BELGIUM
View details

Yun Wei

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Miguel Marcos

Catedrático de Universidad con plaza vinculada

Universidad de Salamanca

SPAIN
View details

Fermin Sanchez-Guijo

Full-Professor of Medicine (Catedrático de Medicina)

Universidad de Salamanca

SPAIN
View details

Francesc Balaguer

Associate Professor

University of Barcelona

SPAIN
View details

Esther Rheinbay

Massachusetts General Hospital

UNITED STATES
View details

Alberto Orfao

-

SPAIN
View details

Maartje Nielsen

Clinical geneticist

Leiden University Medical Center

NETHERLANDS
View details

Mercedes Garayoa

Instituto de Investigación Biomédica de Málaga

SPAIN
View details

Enrique M. Ocio

Head of the Department

Marqués de Valdecilla University Hospital

SPAIN
View details

Roberto Corchado Cobos

-

SPAIN
View details

Jose Maria sayagues

Universidad de Salamanca

SPAIN
View details

Antonino Spinelli

Full Professor od Surgery

Humanitas University

ITALY
View details

Julia Almeida

Full Proffesor

Universidad de Salamanca

SPAIN
View details

Rogelio González-Sarmiento

Catedrático

Universidad de Salamanca

SPAIN
View details